Patents Assigned to Fox Chase Cancer Center
  • Publication number: 20240016957
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 18, 2024
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Publication number: 20230372545
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: October 27, 2022
    Publication date: November 23, 2023
    Applicant: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Publication number: 20220041679
    Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.
    Type: Application
    Filed: October 15, 2018
    Publication date: February 10, 2022
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventors: Jose Russo, Yanrong Su, Julia Santucci Pereira Del Buono, Mark Andrake
  • Publication number: 20210188935
    Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.
    Type: Application
    Filed: October 15, 2018
    Publication date: June 24, 2021
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventors: Jose Russo, Yanrong Su, Julia Santucci Pereira Del Buono, Mark Andrake
  • Patent number: 10450613
    Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 22, 2019
    Assignee: Fox Chase Cancer Center
    Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
  • Patent number: 10449200
    Abstract: Methods for treating tumors comprise contacting tumor cells expressing the vitamin D receptor with a vitamin D receptor ligand that inhibits homologous recombination in the tumor cells, and contacting the tumor cells with an amount of a Poly(ADP) Ribose Polymerase 1 (PARP-1) inhibitor. Inhibiting homologous recombination produces a synergistic therapeutic effect between the vitamin D receptor ligand and PARP-1 inhibitor, and may overcome PARP-1 resistance in killing tumor cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 22, 2019
    Assignee: The Research Institute of Fox Chase Cancer Center
    Inventors: Timothy J. Yen, Vikram Bhattacharjee
  • Publication number: 20190211359
    Abstract: RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.
    Type: Application
    Filed: July 5, 2017
    Publication date: July 11, 2019
    Applicant: Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center
    Inventors: Siddharth Balachandran, Roshan Thapa
  • Patent number: 9611321
    Abstract: Methods for generating hybrid antibodies are provided.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: April 4, 2017
    Assignee: Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Heidi H. Simmons, Matthew K. Robinson, Roland Dunbrack, Andreas Lehmann
  • Patent number: 9522078
    Abstract: An apparatus and method are provided for positioning a patient on a surgical platform. The apparatus includes an elongated flexible web and a plurality of extension straps for connecting the apparatus to the surgical platform. Each extension strap includes a connector configured for connecting the apparatus to the platform. Adjustment mechanisms allow the extension straps to be adjusted to vary the tension in the web. The medical professional selects the desired position and orientation of the patient on the surgical platform and manipulates the patient into the desired position and orientation. A retention device is connected to a surgical platform and placed over the patient at the appropriate portion of the patient. A second end of the retention device is connected to a second side of the surgical platform. The retention device is then adjusted to increase the tension in the retention device.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: December 20, 2016
    Assignee: FOX CHASE CANCER CENTER
    Inventor: Mark-Alan D. Pizzini
  • Patent number: 9451904
    Abstract: An apparatus is provided, which utilizes an adjustment platform for supporting a subject during the endoscopic examination. Additionally, a method for performing an endoscopic examination is also provided in which an endoscope is inserted into a subject and the endoscope is maintained at a generally fixed position while the position of the subject is adjusted to advance the endoscope into the subject. Further still, a method is provided for estimating the size of sample tissue using an endoscope and a reference element. Based on known parameters of the reference element, the size of the area being examined can be estimated.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: September 27, 2016
    Assignee: FOX CHASE CANCER CENTER
    Inventors: Harvey Hensley, Margie Clapper
  • Patent number: 9346814
    Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 24, 2016
    Assignees: Universiteit Antwerp, Fox Chase Cancer Center
    Inventors: Koen Jansen, Ingrid De Meester, Leen Heirbaut, Jonathan D Cheng, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
  • Patent number: 9296687
    Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 29, 2016
    Assignees: Fox Chase Cancer Center, The Trustees of the University of Pennsylvania
    Inventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
  • Publication number: 20150353928
    Abstract: The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, CYR61, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, PTK7, RPS2, SCNN1A, SF3A3, TAF2, TOB1, TSC22D4.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 10, 2015
    Applicants: Georgetown University, Fox Chase Cancer Center
    Inventor: Louis M. WEINER
  • Patent number: 9181322
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 10, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Patent number: 9150636
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 6, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Patent number: 9101631
    Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: August 11, 2015
    Assignees: Georgetown University, Fox Chase Cancer Center
    Inventors: Vladimir Ratushny, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner, Igor Astsaturov, Andrew Godwin
  • Publication number: 20150119263
    Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 30, 2015
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, FOX CHASE CANCER CENTER
    Inventors: Alan T. Johnson, JR., Mitchell Lerner, Matthew K. Robinson, Tatiana Pazina, Dustin Brisson, Jennifer Dailey
  • Patent number: 8980258
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: March 17, 2015
    Assignees: The Regents of the University of California, Fox Chase Cancer Center
    Inventors: Gregory P Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Publication number: 20140357650
    Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 4, 2014
    Applicant: Fox Chase Cancer Center
    Inventors: Koen Jansen, Ingrid De Meester, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
  • Publication number: 20140272947
    Abstract: A high-throughput method for identifying a compound or biomolecule that modulates cell senescence involves simultaneously measuring in a cell population exposed to the test compound or biomolecule, the expression of a senescence marker and cell number, wherein each well contains a single test compound; and determining from said simultaneous measurements whether the test compound increases or decreases cell senescence. In various embodiments, the method is useful is identifying compounds that delay the aging process of normal healthy cells, or identifying a compound useful as a tumor suppressor or identifying a compound useful in the treatment of cancer.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicants: Fox Chase Cancer Center, The Wistar Institute of Anatomy and Biology
    Inventors: Rugang Zhang, Benjamin Guy Bitler, Jeffrey Peterson